What is needed is not just new assays, technology and ideas. It is new organisations, influencers and shared working. A generation Y approach for generation Y times.

The shape of medicines R&D has transformed. Much like the story of Hollywood studies but at an alarming rate, the industry has shifted from an in-house institution to a highly-distributed, multi-party collaboration. This brings logistical benefits as well as challenges that are discussed elsewhere. The larger question for today, however is, does the work we do in discovery and early development adequately reflect patient’s priorities? ..........

You just need to REGISTER - its FREE - to read the rest of this article straight away.